BioLineRx Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BLRX Nasdaq 2836 www.biolinerx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioLineRx Ltd.

BioLineRx Issues Letter to Shareholders - Jan 21st, 2025 12:00 pm
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares - Jan 17th, 2025 12:00 pm
BioLineRx Announces $10 Million Registered Direct Offering - Jan 6th, 2025 1:55 pm
BLRX: Ayrmid Assumes Commercialization Efforts - Dec 3rd, 2024 4:11 pm
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts - Nov 26th, 2024 3:00 pm
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value - Nov 25th, 2024 12:00 pm
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Nov 22nd, 2024 11:35 am
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd. - Nov 21st, 2024 11:30 am
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Nov 20th, 2024 12:19 pm
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - Nov 5th, 2024 2:00 pm
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide - Oct 16th, 2024 11:00 am
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection - Sep 17th, 2024 5:01 pm
BLRX: On Track for 60% Formulary Placement - Aug 20th, 2024 9:41 am
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - Aug 15th, 2024 11:00 am
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - Aug 8th, 2024 11:00 am
BLRX: First Quarter 2024 Results - Jun 10th, 2024 10:36 am
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 - Jun 5th, 2024 7:17 pm
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - May 30th, 2024 11:00 am
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - May 28th, 2024 11:00 am
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting - May 24th, 2024 11:00 am